Business Context and Reporting Period
This Form 6-K filing by EUDA Health Holdings Ltd covers the month of November 2025, with the report dated November 17, 2025. The filing details the final conversion of a convertible promissory note issued under a purchase agreement dated August 1, 2025.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or margin data. The specific financial activity reported is the conversion of debt to equity:
- Total Note Principal: $1,000,000 (August Note).
- Previously Converted: $837,500 into 569,859 ordinary shares.
- Additional Shares Issued (Sept/Oct): 41,620 ordinary shares at $0.901 per share.
- Final Conversion (Nov 7, 2025): Remaining $162,500 balance converted into 81,250 ordinary shares at $2.00 per share.
- Remaining Debt: $0 (August Note fully converted).
Material Changes
The primary material change is the full conversion of the $1,000,000 August Note into ordinary shares, eliminating the associated debt obligation. On November 7, 2025, the Purchaser elected to convert the remaining $162,500 balance rather than requesting cash repayment. Additionally, the Company confirmed it does not intend to issue further put requests for additional Notes under the original Purchase Agreement.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, revenue outlook, or management commentary regarding future operations. The document notes that the description of the October Amendment to the Letter Agreement is qualified by reference to the full text filed as Exhibit 1.1. No specific risks or contingencies beyond the terms of the note conversion are detailed in this summary text.
Investor Verification Checklist
- Verify the total number of ordinary shares issued upon full conversion of the August Note (569,859 + 41,620 + 81,250).
- Confirm the dilution impact of the 81,250 shares issued at the $2.00 conversion price.
- Review Exhibit 1.1 (October Amendment to Letter Agreement) for any covenants or conditions not summarized in the text.
- Check subsequent filings for any new debt instruments or equity issuances, as the Company has ceased issuing additional Notes under the August 2025 agreement.